[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"male-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:male-breast-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100477802","phase-2-ethan---et-for-male-bc-100477802",false,"NCT05501704","ETHAN - ET for Male BC","ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer","Inclusion Criteria:\n\n* Men aged 18 years or older, with diagnosis of invasive breast cancer who have not undergone surgical resection of the primary tumor and axillary nodes.\n* Stage I, II, or III per American Joint Committee on Cancer (AJCC) staging 8th edition (112).\n* Breast cancer must be hormone receptor-positive and HER2-negative according to definition below assessed by local pathology.\n\n  * Hormone receptor-positive is defined as: positivity for at least one of the hormone receptors (estrogen receptor \\[ER\\] or progesterone receptor \\[PR\\]) by IHC. ER and PR assays are considered positive if there are \\> 1% positive tumor nuclei in the samples.\n  * HER2-negative is defined per the current American Society of Clinical Oncology\u002FCollege of American Pathologists Clinical Practice Guideline (113).\n* Patients with multifocal or multicentric disease are eligible if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative.\n* Bilateral breast cancers are allowed if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative.\n* Patients with a history of ipsilateral or contralateral DCIS or LCIS are eligible.\n* ECOG performance status ≤ 2.\n* Required laboratory values demonstrating adequate organ function:\n\n  * ANC ≥ 1000\u002Fmm3\n  * Hemoglobin ≥ 8 g\u002Fdl\n  * Platelets ≥ 50,000\u002Fmm3\n  * Serum creatinine ≤ 3.0 x ULN (institutional)\n  * Total bilirubin ≤ 2.0 x ULN (institutional).\n  * AST and ALT ≤ 5.0 x ULN (institutional)\n* Men with partners of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and\u002For partner and continue its use for the duration of the study treatment and for 6 months after the last dose of study treatment.\n* Non-English-speaking patients are eligible but will be exempt from patient-completed questionnaires.\n* Willing and able to sign informed consent.\n* Willing to undergo breast biopsy after completion of window phase.\n* Patient is able to swallow oral medications.\n\nExclusion Criteria:\n\n* Prior endocrine therapy, chemotherapy, radiation therapy, or investigational therapy for the current breast cancer diagnosis.\n* Prior endocrine therapy, systemic therapy, radiation therapy, or investigational therapy for any other malignancy within the past 12 months.\n* Diagnosis of inflammatory breast cancer (T4d).\n* Other concurrent serious diseases that may interfere with planned treatment, including severe cardiac disease, congestive heart failure (CHF) of New York Heart Association (NYHA) Class III or higher, severe pulmonary conditions\u002Fillness, uncontrolled infections.\n* The patient has serious and\u002For uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \\[e.g. estimated creatinine clearance \\\u003C30ml\u002Fmin\\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).\n* The patient has active systemic bacterial infection (requiring intravenous \\[IV\\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \\[for example, hepatitis B surface antigen positive\\]. Screening is not required for enrollment.\n* The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.","MALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer.\n\nThe drugs used in this study are:\n\n* Tamoxifen\n* Anastrozole\n* Degarelix\n* Abemaciclib",[26,27,28],"Male Breast Cancer","Hormone Receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma",[26,27,30],"Hormone Receptor Negative Breast Cancer","RECRUITING","2026-04-27",{"date":34,"type":35},"2026-04-30","ACTUAL",{"date":37,"type":35},"2023-10-11",{"date":39,"type":20},"2036-04-01",{"name":41,"class":42},"Jose Pablo Leone","OTHER",8,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100635873","male-breast-cancer-predisposition-factor-creation-of-a-control-cohort-2-100635873","NCT07558343","Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2","MATADOR2","Inclusion Criteria:\n\n* 1\\. A male volunteer participant with no personal history of cancer, registered in the IUCT-O oncogenetics database as a relative of a patient carrying a pathogenic or likely pathogenic variant in one of the cancer predisposition genes routinely analyzed at the oncogenetics laboratory\n* 2\\. Age ≥ 66 years\n* 3\\. Participant with no known family relationship to a patient of the MATADOR1 cohort\n* 4\\. Participant who has undergone an oncogenetic consultation at the IUCT-O\n* 5\\. Participant who does not carry the familial mutation in any of the cancer predisposition genes previously tested\n* 6\\. Participant for which an archived blood sample is available for the research in the oncogenetics laboratory\n* 7\\. Participant having signed an informed consent form before inclusion in the study and before any study specific procedure\n\nExclusion Criteria:\n\n* 1\\. Patient who has forfeited his\u002Fher freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).","66 Years",{"count":53,"type":20},120,[55],"NA","This is an interventional, prospective, single-center study designed to collect and describe genetic, environmental and psychosocial control data from male participants. The participants did not have any prior history of cancer at the time of the oncogenetic consultation and do not have the family mutation researched during the oncogenetic consultation (targeted genetic testing). The participants are referenced in the IUCT-O medical records as family members of patients suffering from male breast cancer.\n\nThe study will be conducted on a population of 120 participants.",[26],[59,60],"breast cancer","predisposition factor","NOT_YET_RECRUITING","2026-04-23",{"date":34,"type":35},{"date":65,"type":20},"2026-06-15",{"date":67,"type":20},"2027-07-15",{"name":69,"class":42},"Institut Claudius Regaud",1]